Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR2C | P28335 | 19/20 | 1.00 |
| ▸ | HTR2A | P28223 | 5/20 | 1.00 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 1.00 |
| ▸ | CYP1A2 | P05177 | 1/20 | 1.00 |
| ▸ | CYP3A4 | P08684 | 1/20 | 1.00 |
| ▸ | CYP2D6 | P10635 | 1/20 | 1.00 |
| ▸ | CYP2C9 | P11712 | 1/20 | 1.00 |
| ▸ | CYP2C19 | P33261 | 1/20 | 1.00 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.43 |
| ▸ | MAPT | P10636 | 1/20 | 0.43 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.43 |
| ▸ | HTR2B | P41595 | 4/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL905974 | 1.00 | HTR2C (1.00) | HTR2CHTR2AALDH1A1CYP1A2CYP3A4 | |
| SCHEMBL5872568 | 1.00 | HTR2C (1.00) | HTR2CHTR2AALDH1A1CYP1A2CYP3A4 | |
| SCHEMBL29391309 | 1.00 | HTR2C (1.00) | HTR2CHTR2AALDH1A1CYP1A2CYP3A4 | |
| Hydrochloric Acid SCHEMBL6775134 | 0.99 | HTR2C (0.97) | HTR2CHTR2AALDH1A1CYP1A2CYP3A4 | |
| Hydrochloric Acid SCHEMBL1986324 | 0.99 | HTR2C (0.97) | HTR2CHTR2AALDH1A1CYP1A2CYP3A4 | |
| Hydrochloric Acid SCHEMBL5872551 | 0.99 | HTR2C (0.97) | HTR2CHTR2AALDH1A1CYP1A2CYP3A4 | |
| SCHEMBL15307687 | 0.89 | HTR2C (0.81) | HTR2CHTR2AALDH1A1CYP1A2CYP3A4 | |
| SCHEMBL5872582 | 0.86 | HTR2C (1.00) | HTR2CHTR2AALDH1A1CYP1A2CYP3A4 | |
| SCHEMBL5872550 | 0.86 | HTR2C (1.00) | HTR2CHTR2AALDH1A1CYP1A2CYP3A4 | |
| SCHEMBL5872559 | 0.86 | HTR2C (1.00) | HTR2CHTR2AALDH1A1CYP1A2CYP3A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 81 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20060211700-A1 | (R)-8,9-dichloro-2,3,4,4a-tetrahydro-1H,6H-pyrazino[1,2-a]quinoxalin-5-one for controlling IOP and treating glaucoma | ALCON, INC. | 2006-09-21 | — | — | US | claimed |
| US-7098338-B2 | 2,3,4,4a-tetrahydro-1H-pyrazino(1,2-a) quinoxalin-5(6H)one derivatives | WYETH (US) | 2006-08-29 | — | — | US | claimed |
| US-20040116437-A1 | 2,3,4,4a-tetrahydro-1H-pyrazino(1,2-a) quinoxalin-5(6H)one derivatives | WYETH (US) | 2004-06-17 | — | — | US | claimed |
| US-6706714-B2 | USEFUL FOR THE TREATMENT OF DISORDERS INVOLVING THE CENTRAL NERVOUS SYSTEM SUCH AS OBSESSIVE-COMPULSIVE DISORDER, DEPRESSION, ANXIETY, SCHIZOPHERNIA, MIGRAINE, SLEEP OR EATING DISORDER, OBESITY, TYPE II DIABETES AND EPILEPSY | WYETH CORP (US) | 2004-03-16 | — | — | US | claimed |
| US-20030060468-A1 | 2,3,4,4a-Tetrahydro-1H-pyrazino[1,2-a]quinoxalin-5(6H)one derivatives | WYETH (US) | 2003-03-27 | — | — | US | claimed |
| US-6476032-B2 | 5HT2C RECEPTOR AGONISTS TO TREAT SCHIZOPHRENIA AND CENTRAL NERVOUS SYSTEM DISORDERS; OBSESSIVE-COMPULSIVE DISORDER; ANTIDEPRESSANTS, MIGRAINE; SLEEP DISORDERS; EATING DISORDERS; OBESITY; ANTIDIABETIC, -EPILEPTIC AND ANXIOLYTIC AGENTS | WYETH | 2002-11-05 | — | — | US | claimed |
| US-6372745-B1 | TREATMENT OF OBESITY IN MAMMALS | AMERICAN HOME PRODUCTS CORPORATION | 2002-04-16 | — | — | US | claimed |
| US-20010051622-A1 | 2,3,4,4a-tetrahydro-1H-pyrazino-[1,2a] quinoxalin-5- (6H) one derivatives | AMERICAN HOME PRODUCTS CORPORATION (US) | 2001-12-13 | — | — | US | claimed |
| EP-1140940-A1 | 2,3,4,4A-TETRAHYDRO-1H-PYRAZINO(1,2-A)QINOXALIN-5(6H)ONE DERIVATES BEING 5HT2C AGONISTS | AMERICAN HOME PRODUCTS CORPORATION (US) | 2001-10-10 | — | — | EP | claimed |
| EP-1115707-A1 | BENZAMIDE DERIVATIVES AND THER USE AS CYTOKINE INHIBITORS | AstraZeneca AB (SE) | 2001-07-18 | — | — | EP | claimed |
| WO-2000035922-A1 | 2,3,4,4A-TETRAHYDRO-1H-PYRAZINO(1,2-A)QUINOXALIN-5(6H)ONE DERIVATES BEING 5HT2C AGONISTS | AMERICAN HOME PRODUCTS CORPORATION (US) | 2000-06-22 | — | — | WO | claimed |
| WO-2000018738-A1 | BENZAMIDE DERIVATIVES AND THEIR USE AS CYTOKINE INHIBITORS | ASTRAZENECA AB (SE) | 2000-04-06 | — | — | WO | claimed |
| US-20250177354-A1 | THERAPEUTIC COMBINATIONS, COMPOSITIONS, AND METHODS FOR DESIGNING AND PRODUCING ENTACTOGENIC MINDSTATES | MINDSTATE DESIGN LABS INC (US) | 2025-06-05 | — | — | US | disclosed |
| EP-2531485-B1 | HIGHLY SELECTIVE 5-HT(2C) RECEPTOR AGONISTS HAVING ANTAGONIST ACTIVITY AT THE 5-HT(2B) RECEPTOR | UNIV ILLINOIS (US) | 2019-04-24 | — | — | EP | disclosed |
| US-20150238506-A1 | FUSED HETEROCYCLIC COMPOUND AND USE THEREOF | TAKEDA PHARMACEUTICAL (JP) | 2015-08-27 | — | — | US | disclosed |
| US-20150238506-A1 | FUSED HETEROCYCLIC COMPOUND AND USE THEREOF | TAKEDA PHARMACEUTICAL (JP) | 2015-08-27 | — | — | US | disclosed |
| EP-1115707-A1 | BENZAMIDE DERIVATIVES AND THER USE AS CYTOKINE INHIBITORS | AstraZeneca AB (SE) | 2001-07-18 | — | — | EP | disclosed |
| WO-2000035922-A1 | 2,3,4,4A-TETRAHYDRO-1H-PYRAZINO(1,2-A)QUINOXALIN-5(6H)ONE DERIVATES BEING 5HT2C AGONISTS | AMERICAN HOME PRODUCTS CORPORATION (US) | 2000-06-22 | — | — | WO | disclosed |
| WO-2000018738-A1 | BENZAMIDE DERIVATIVES AND THEIR USE AS CYTOKINE INHIBITORS | ASTRAZENECA AB (SE) | 2000-04-06 | — | — | WO | disclosed |
| US-4203987-A | HYPOTENSIVE AGENTS, ANTISECRETORY AGENTS, ANTIULCER AGENTS | AMERICAN HOME PRODUCTS CORPORATION (US) | 1980-05-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250177354-A1 | THERAPEUTIC COMBINATIONS, COMPOSITIONS, AND METHODS FOR DESIGNING AND PRODUCING ENTACTOGENIC MINDSTATES | CNR2, CNR1, HTR6 | HTR2C 5/4885HTR2A 12/4885ALDH1A1 3956/4885 |
| US-20030060468-A1 | 2,3,4,4a-Tetrahydro-1H-pyrazino[1,2-a]quinoxalin-5(6H)one derivatives | NPY2R, HCRTR2, HTR2C | HTR2C 3/4885HTR2A 10/4885ALDH1A1 1969/4885 |
| US-20010051622-A1 | 2,3,4,4a-tetrahydro-1H-pyrazino-[1,2a] quinoxalin-5- (6H) one derivatives | HTR2C, HTR3C, NPY2R | HTR2C 1/4885HTR2A 5/4885ALDH1A1 2135/4885 |
| US-20150238506-A1 | FUSED HETEROCYCLIC COMPOUND AND USE THEREOF | HTR2C, HTR3C, HTR3B | HTR2C 1/4885HTR2A 4/4885ALDH1A1 822/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.